Close

7DW8-5

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EF77 is a plakoside A-like glycolipid, a GSL isolated from the marine sponge, Plakortis simplex, and is related to the previously crystallized SMC124 lipid. The sugar headgroup and O-glycosidic linkage are identical to GalCer, but the acyl chain has been modified to mimic plakoside A, with a cyclopropyl group and double bond between carbons 4 and 5. Like EF77, 7DW8-5 also has a modification in the acyl group. The length of the chain has been shortened to 11 carbons and a parafluor-phenyl group has been added. The rationale behind those different modifications is that changes in the lipid moiety would be expected to mainly influence the lipid interaction with CD1d, whereas changes in the galactose moiety and linkage can affect interaction with CD1d; the TCR and they could confer resistance to endoglycosidases upon injection into mice and thus could increase the half-life in serum.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0047 Mouse anti-7DW8-5 T cell receptor (Vα14Vβ8.2), pCDTCR1 Vα14Vβ8.2 Mouse 7DW8-5 mouse CD1d Lentiviral vector   Add to Cart   Datasheet
TCR-YC0048 Human anti-7DW8-5 T cell receptor (Vα24Vβ11), pCDTCR1 Vα24Vβ11 Human 7DW8-5 human CD1d Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.